Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.

Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK.

Cancer. 2006 Jul 15;107(2):417-22.

2.

Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.

Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S.

J Clin Oncol. 2014 Feb 20;32(6):527-34. doi: 10.1200/JCO.2013.51.2038. Epub 2014 Jan 13.

3.

[The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].

Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG.

HNO. 2007 Apr;55(4):299-306. German.

PMID:
16437215
4.

The incidence of hearing impairment after successful treatment of neuroblastoma.

Simon T, Hero B, Dupuis W, Selle B, Berthold F.

Klin Padiatr. 2002 Jul-Aug;214(4):149-52.

PMID:
12165893
5.

Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.

Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O.

J Pediatr Hematol Oncol. 2004 Oct;26(10):649-55.

PMID:
15454836
6.

[Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].

Biró K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I.

Magy Onkol. 2006;50(4):329-35. Epub 2007 Jan 10. Hungarian.

7.

Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.

Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, Deuster D, Seifert E, Würthwein G, Jaehde U, Pieck AC, Boos J.

Pediatr Blood Cancer. 2006 Aug;47(2):183-93.

PMID:
16302218
8.

Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.

Marina N, Chang KW, Malogolowkin M, London WB, Frazier AL, Womer RB, Rescorla F, Billmire DF, Davis MM, Perlman EJ, Giller R, Lauer SJ, Olson TA; Children's Oncology Group..

Cancer. 2005 Aug 15;104(4):841-7.

9.

Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.

Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L.

Br J Cancer. 1998 Apr;77(8):1355-62.

11.

Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.

Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD; German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology..

Cancer Invest. 2005;23(3):201-7.

PMID:
15945505
12.

Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma.

Parsons SK, Neault MW, Lehmann LE, Brennan LL, Eickhoff CE, Kretschmar CS, Diller LR.

Bone Marrow Transplant. 1998 Oct;22(7):669-74.

13.

Ototoxicity in children treated for osteosarcoma.

Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE.

Pediatr Blood Cancer. 2009 Mar;52(3):387-91. doi: 10.1002/pbc.21875.

PMID:
19061216
14.

Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.

Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D.

Ear Hear. 2008 Dec;29(6):875-93. doi: 10.1097/AUD.0b013e318181ad99.

PMID:
18753950
15.

[Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].

Montaguti M, Brandolini C, Ferri GG, Hatzopoulos S, Prete A, Pession A.

Acta Otorhinolaryngol Ital. 2002 Feb;22(1):14-8. Italian.

PMID:
12236007
16.

Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.

Jehanne M, Lumbroso-Le Rouic L, Savignoni A, Aerts I, Mercier G, Bours D, Desjardins L, Doz F.

Pediatr Blood Cancer. 2009 May;52(5):637-43. doi: 10.1002/pbc.21898.

PMID:
19148943
17.

Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.

Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ.

J Pediatr Hematol Oncol. 2008 Feb;30(2):130-4. doi: 10.1097/MPH.0b013e31815d1d83.

PMID:
18376265
18.

Assessment of cisplatin-induced ototoxicity using derived-band ABRs.

Coupland SG, Ponton CW, Eggermont JJ, Bowen TJ, Grant RM.

Int J Pediatr Otorhinolaryngol. 1991 Oct;22(3):237-48.

PMID:
1752735
19.

Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.

Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, Rasch CR, Balm AJ.

J Clin Oncol. 2007 Aug 20;25(24):3759-65.

PMID:
17704425
20.

Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach.

Orgel E, Jain S, Ji L, Pollick L, Si S, Finlay J, Freyer DR.

Pediatr Blood Cancer. 2012 Jun;58(6):953-8. doi: 10.1002/pbc.23275. Epub 2011 Jul 27.

PMID:
21796767

Supplemental Content

Support Center